Recent Finacing
Recent Raise
ImmunoMet Therapeutics is a clinical-stage biotech developing metabolism-targeted anti-fibrotic and anti-cancer therapies, including IM156 (PC1/OXPHOS inhibitor) and preclinical immuno-oncology programs plus biguanide library.
